STTCOMP PTX TA LONG
CAR T Cancer therapies and Platform tech
Lets start out by admitting this chart is horrendous viewing.
Arguments for entry are a mix of TA and FA
Retraced to a baseline support
Volume on decline has been very low - relatively - disgruntled short termers have given up
RSI is now oversold
BB's are tightening
Results for year long trial with tier 1 partner due in next few weeks
CAR T plyers starting to see some M&A action
FDA are perceived to be leaning towards allowing therapies that may not have reached Phase III , if all else has failed
I am adding down here. They are going to need cash for trials but I suspect that comes from partners interested in their unique platform technologies. i think the next 8 weeks are going to see some healthy returns for the comp, but I think longer term tis is a good point to accumulate a few more
AUD$50m mkt cap is a joke - that's about US$33m and what most US biotech investors would call a steal.
- Forums
- ASX - Short Term Trading
- Short Term Trading Week Starting: 21 Aug
Short Term Trading Week Starting: 21 Aug, page-4
Featured News
Featured News
The Watchlist
NUZ
NEURIZON THERAPEUTICS LIMITED
Dr Michael Thurn, CEO & MD
Dr Michael Thurn
CEO & MD
SPONSORED BY The Market Online